Exploring the Data Integrity Ordinance in Pharmaceutical Domain
1★, 2, 1★ Corresponding author
- 1Department of Quality Assurance, L J Institute of Pharmacy, LJ University, Ahmedabad, Gujarat, INDIA.
- 2Department of Regulatory Affairs, L J Institute of Pharmacy, LJ University, Ahmedabad, Gujarat, INDIA.
CORRESPONDENCE
Darshil B Shah
Department of Quality Assurance, L J Institute of Pharmacy, LJ University, Ahmedabad, Gujarat, INDIA.
Received: 20-06-2022; Revised: 04-07-2022; Accepted: 27-08-2022.
Volume 14, Issue 4 · pp. 377-381 · 2022 · DOI: 10.5530/jyp.2022.14.76
ABSTRACT
With the revolutionary expedition of technologies being used in pharmaceutical world to collect and process data, the honesty of data is predominant factor and subject to preservation. If the data collection of the products soon to be marketed, is adulterated it would not only be a potential harm to general public but also cause of economical and reputational damage for manufacturers. To secure the value of crucial data, regulatory authorities has been producing guidance regarding the integrity of data. Data integrity guarantees that data is not tampered with be it paper or electronic. Protecting the integrity, whether electronic or handwritten, is essential for making sound business decisions. In attempt of introducing aspects of data, the FDA first developed the ALCOA principles which are still the first line defence of integrity breaches in pharmaceutical companies. With the changing times of technologies, FDA evolved the data integrity principles into requirements and specifications of current good manufacturing practice answering questions directly from manufacturers. To understand the basic yet complex terms and conditions, this article strives to outline the Data Integrity requirements of USFDA specified in its cGMP guidance for data integrity specifications
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Shah, D. B., Shah, J. S., & Maheshwari, D. G. (2022). Exploring the Data Integrity Ordinance in Pharmaceutical Domain. Journal of Young Pharmacists, 14(4), 377-381. https://doi.org/10.5530/jyp.2022.14.76
Copyright and licence
© 2022 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0
